Simple blood test can accurately reveal underlying neurodegeneration
A new study of more than 3,000 people, led by King’s College London in collaboration with Lund University, has shown for the first time that a single biomarker, a naturally occurring molecule or gene, can accurately indicate the presence of underlying neurodegeneration in people with cognitive issues.
Neurodegenerative diseases are debilitating conditions that result in ongoing degeneration or death of nerve cells, leading to problems in thought, attention and memory. There are currently around 850,000 people with dementia in the UK which is projected to rise to 1.6 million by 2040. In order to help identify the onset of these debilitating diseases and put in place preventative measures as early as possible there has been a drive to develop reliable and accessible biomarkers that can recognise or rule out whether the processes in the brain that are responsible for neurodegeneration are occurring.
Levels of a protein called neurofilament light chain (NfL) in the blood can identify those who might have neurodegenerative diseases such as Down’s syndrome dementia, Motor Neuron Disease and frontotemporal dementia, when clinical symptoms are not definitive.
Published in Nature Communications and part-funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC), the research determined a set of age-related cut-off levels of NfL which could inform its potential use in primary care settings through a simple blood test.
Joint Senior Author on the study, Dr Abdul Hye from the NIHR Maudsley BRC at King’s College London and South London and Maudsley NHS Foundation Trust, said:
For the first time we have shown across a number of disorders that a single biomarker can indicate the presence of underlying neurodegeneration with excellent accuracy. Though it is not specific for any one disorder, it could help in services such as memory clinics as a rapid screening tool to identify whether memory, thinking or psychiatric problems are a result of neurodegeneration.
Current biomarkers used to identify neurodegenerative disorders are taken from the fluid that surrounds the brain and spinal column (cerebrospinal fluid - CSF) which has to be extracted using an invasive procedure called ‘lumbar puncture’. Advances have been made to use biomarkers from the blood which would provide a more accessible and comfortable assessment. A central and irreversible feature in many neurodegenerative disorders is damage to the nerve fibre which results in the release of NfL. Using ultrasensitive tests, NfL can be detected in blood at low levels and is increased in a number of disorders, unlike phosphorylated tau which is specific for Alzheimer’s disease. This means NfL can be of use in the diagnostic process of many neurodegenerative diseases most notably in this study Down’s syndrome dementia, ALS and frontotemporal dementia.
Co-author Prof Ammar Al-Chalabi, King’s College London and co-lead of the Psychosis and Neuropsychiatry research theme at the NIHR Maudsley BRC, said”
For neurodegenerative diseases like Alzheimer’s, Parkinson’s or motor neuron disease, a blood test to allow early diagnosis and help us monitor disease progression and response to treatment would be very helpful. Neurofilament light chain is a promising biomarker that could speed diagnosis of neurodegenerative diseases and shorten clinical trials.
The study examined 3,138 samples from King’s College London, Lund University and Alzheimer’s Disease Neuroimaging Initiative, including people with no cognitive impairment, people with neurodegenerative disorders, people with Down syndrome and people with depression. The study showed that concentrations of NfL in the blood were higher across all neurodegenerative disorders compared to those with no cognitive problems, the highest being in people with Down’s syndrome dementia, motor neuron disease and frontotemporal dementia.
The study also showed that although blood based NfL could not differentiate between all the disorders, it could provide insight into different groups within certain disorders. For example, in those with Parkinson’s disease a high concentration of NfL indicated atypical Parkinson’s disorder and in patients with Down syndrome, NfL levels differentiated between those with and without dementia.
Read the article in full on the King’s College London website.
We are using our collective expertise to become a global top ten Neurosciences Institute, demonstrated through excellence in research, education and clinical practice.